Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Stifel Financial Corp

Stifel Financial Corp reduced its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 13.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 86,691 shares of the medical equipment provider's stock after selling 13,872 shares during the period. Stifel Financial Corp's holdings in Zimmer Biomet were worth $9,359,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in shares of Zimmer Biomet in the 2nd quarter worth approximately $43,000. Assenagon Asset Management S.A. raised its position in shares of Zimmer Biomet by 3.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 24,286 shares of the medical equipment provider's stock valued at $2,636,000 after buying an additional 815 shares in the last quarter. Rovin Capital UT ADV lifted its holdings in shares of Zimmer Biomet by 13.6% in the 2nd quarter. Rovin Capital UT ADV now owns 5,397 shares of the medical equipment provider's stock valued at $586,000 after acquiring an additional 645 shares during the last quarter. Gradient Investments LLC grew its position in Zimmer Biomet by 17.3% in the second quarter. Gradient Investments LLC now owns 130,350 shares of the medical equipment provider's stock worth $14,147,000 after acquiring an additional 19,224 shares in the last quarter. Finally, Boomfish Wealth Group LLC increased its stake in Zimmer Biomet by 19.5% during the second quarter. Boomfish Wealth Group LLC now owns 11,387 shares of the medical equipment provider's stock worth $1,236,000 after acquiring an additional 1,855 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock traded down $0.07 during midday trading on Thursday, hitting $106.84. The company had a trading volume of 1,208,196 shares, compared to its average volume of 1,486,600. The company has a fifty day simple moving average of $107.59 and a 200 day simple moving average of $108.83. The stock has a market cap of $21.27 billion, a price-to-earnings ratio of 20.34, a PEG ratio of 1.99 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.74. The company had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm's quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the business posted $1.65 EPS. As a group, analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Royal Bank of Canada lifted their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an "outperform" rating in a research note on Monday, November 4th. BTIG Research cut their target price on Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating on the stock in a research note on Thursday, October 3rd. Truist Financial raised their price target on Zimmer Biomet from $112.00 to $117.00 and gave the stock a "hold" rating in a research note on Friday, November 1st. Barclays cut their price target on shares of Zimmer Biomet from $125.00 to $118.00 and set an "underweight" rating on the stock in a report on Thursday. Finally, Canaccord Genuity Group dropped their price objective on Zimmer Biomet from $120.00 to $115.00 and set a "hold" rating on the stock in a research note on Tuesday, September 10th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $122.83.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.